Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
- LifeScan Japan Taps AI to Fast-Track Sales Force Development, Draws Interest from Pharma
October 29, 2025
- J-TEC, AlliedCel Ink Service Contract for T-Cell Therapy Production
October 29, 2025
- Japan Gives Orphan Tags for Kyowa Kirin’s Gene Therapy, Cuorips’ Cell Sheet
October 29, 2025
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
- Viatris Begins Japan Enrollment in Global PIII Study for AMI Drug
October 28, 2025
- Medinet Grabs Option for Stempeucel from India’s Stempeutics
October 28, 2025
- Japan Ethical Drug Sales Rise 2.8% in April-September: Encise
October 28, 2025
- First Oral Small-Molecule GLP-1 Nears Filing; Broad Use Expected in Diabetes
October 27, 2025
- Chugai Acquires Renalys Pharma, Bags IgAN Drug
October 27, 2025
- Astellas to Build Next-Gen Pipeline in I/O and Protein Degradation: R&D Chief
October 27, 2025
- AstraZeneca Sees Imfinzi’s Bladder Cancer Nod as Key New Indication
October 27, 2025
- EA Pharma Files to Add Dosage for 1-Year-Olds to Movicol
October 27, 2025
- Teijin Licenses RA Drug Candidate to UK’s Elevara
October 24, 2025
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…